190 related articles for article (PubMed ID: 11420602)
21. Intrinsic resistance to chemotherapeutic agents in murine osteosarcoma cells.
Takeshita H; Kusuzaki K; Ashihara T; Gebhardt MC; Mankin HJ; Hirasawa Y
J Bone Joint Surg Am; 2000 Jul; 82-A(7):963-9. PubMed ID: 10901311
[TBL] [Abstract][Full Text] [Related]
22. Sphingolipid targets in cancer therapy.
Modrak DE; Gold DV; Goldenberg DM
Mol Cancer Ther; 2006 Feb; 5(2):200-8. PubMed ID: 16505092
[TBL] [Abstract][Full Text] [Related]
23. Updates on functions of ceramide in chemotherapy-induced cell death and in multidrug resistance.
Ogretmen B; Hannun YA
Drug Resist Updat; 2001 Dec; 4(6):368-77. PubMed ID: 12030784
[TBL] [Abstract][Full Text] [Related]
24. Cancer and sphingolipid storage disease therapy using novel synthetic analogs of sphingolipids.
Gatt S; Dagan A
Chem Phys Lipids; 2012 May; 165(4):462-74. PubMed ID: 22387097
[TBL] [Abstract][Full Text] [Related]
25. ABCB1 protects kidney proximal tubule cells against cadmium-induced apoptosis: roles of cadmium and ceramide transport.
Lee WK; Torchalski B; Kohistani N; Thévenod F
Toxicol Sci; 2011 Jun; 121(2):343-56. PubMed ID: 21436125
[TBL] [Abstract][Full Text] [Related]
26. β-carotene reverses multidrug resistant cancer cells by selectively modulating human P-glycoprotein function.
Teng YN; Sheu MJ; Hsieh YW; Wang RY; Chiang YC; Hung CC
Phytomedicine; 2016 Mar; 23(3):316-23. PubMed ID: 26969385
[TBL] [Abstract][Full Text] [Related]
27. Immunosuppressors as multidrug resistance reversal agents.
Morjani H; Madoulet C
Methods Mol Biol; 2010; 596():433-46. PubMed ID: 19949935
[TBL] [Abstract][Full Text] [Related]
28. Targeting ceramide metabolism--a strategy for overcoming drug resistance.
Senchenkov A; Litvak DA; Cabot MC
J Natl Cancer Inst; 2001 Mar; 93(5):347-57. PubMed ID: 11238696
[TBL] [Abstract][Full Text] [Related]
29. Synthetic, non-natural sphingolipid analogs inhibit the biosynthesis of cellular sphingolipids, elevate ceramide and induce apoptotic cell death.
Dagan A; Wang C; Fibach E; Gatt S
Biochim Biophys Acta; 2003 Sep; 1633(3):161-9. PubMed ID: 14499735
[TBL] [Abstract][Full Text] [Related]
30. The effect of altered sphingolipid acyl chain length on various disease models.
Park WJ; Park JW
Biol Chem; 2015 Jun; 396(6-7):693-705. PubMed ID: 25720066
[TBL] [Abstract][Full Text] [Related]
31. Sphingolipid/Ceramide Pathways and Autophagy in the Onset and Progression of Melanoma: Novel Therapeutic Targets and Opportunities.
Lai M; La Rocca V; Amato R; Freer G; Pistello M
Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31336922
[TBL] [Abstract][Full Text] [Related]
32. The gut-to-breast connection - interdependence of sterols and sphingolipids in multidrug resistance and breast cancer therapy.
Spassieva S; Bieberich E
Anticancer Agents Med Chem; 2011 Nov; 11(9):882-90. PubMed ID: 21707484
[TBL] [Abstract][Full Text] [Related]
33. Sphingolipids in mitochondria.
Hernández-Corbacho MJ; Salama MF; Canals D; Senkal CE; Obeid LM
Biochim Biophys Acta Mol Cell Biol Lipids; 2017 Jan; 1862(1):56-68. PubMed ID: 27697478
[TBL] [Abstract][Full Text] [Related]
34. Sphingolipids: key regulators of apoptosis and pivotal players in cancer drug resistance.
Giussani P; Tringali C; Riboni L; Viani P; Venerando B
Int J Mol Sci; 2014 Mar; 15(3):4356-92. PubMed ID: 24625663
[TBL] [Abstract][Full Text] [Related]
35. Immunosuppressors and reversion of multidrug-resistance.
Aouali N; Eddabra L; Macadré J; Morjani H
Crit Rev Oncol Hematol; 2005 Oct; 56(1):61-70. PubMed ID: 15978826
[TBL] [Abstract][Full Text] [Related]
36. The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis.
Assaraf YG
Drug Resist Updat; 2006; 9(4-5):227-46. PubMed ID: 17092765
[TBL] [Abstract][Full Text] [Related]
37. Sphingolipids related to apoptosis from the point of view of membrane structure and topology.
van Blitterswijk WJ; van der Luit AH; Caan W; Verheij M; Borst J
Biochem Soc Trans; 2001 Nov; 29(Pt 6):819-24. PubMed ID: 11709081
[TBL] [Abstract][Full Text] [Related]
38. SDZ PSC 833 the drug resistance modulator activates cellular ceramide formation by a pathway independent of P-glycoprotein.
Goulding CW; Giuliano AE; Cabot MC
Cancer Lett; 2000 Feb; 149(1-2):143-51. PubMed ID: 10737718
[TBL] [Abstract][Full Text] [Related]
39. Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance.
Bradshaw DM; Arceci RJ
J Clin Oncol; 1998 Nov; 16(11):3674-90. PubMed ID: 9817290
[TBL] [Abstract][Full Text] [Related]
40. Overexpression of glucosylceramide synthase in associated with multidrug resistance of leukemia cells.
Xie P; Shen YF; Shi YP; Ge SM; Gu ZH; Wang J; Mu HJ; Zhang B; Qiao WZ; Xie KM
Leuk Res; 2008 Mar; 32(3):475-80. PubMed ID: 17709137
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
